Lena Wallensteen
Overview
Explore the profile of Lena Wallensteen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vant Westeinde A, Karlsson L, Messina V, Wallensteen L, Brosamle M, Dal Maso G, et al.
Endocr Connect
. 2023 Feb;
12(4).
PMID: 36752813
First-trimester prenatal treatment with glucocorticoid (GC) dexamethasone (DEX) in pregnancies at risk for classic congenital adrenal hyperplasia (CAH) is associated with ethical dilemmas. Though effective in reducing virilisation in girls...
2.
Karlsson L, Wallensteen L, Nordenstrom A, Krmar R, Lajic S
J Clin Endocrinol Metab
. 2022 Feb;
107(6):e2481-e2487.
PMID: 35148399
Context: The clinical use of dexamethasone (DEX) prenatally to reduce virilization of external genitalia in female fetuses with congenital adrenal hyperplasia (CAH) is efficient but still controversial. It remains challenging...
3.
Wallensteen L, Karlsson L, Messina V, Nordenstrom A, Lajic S
J Clin Endocrinol Metab
. 2020 May;
105(7).
PMID: 32433752
Background: Prenatal treatment with dexamethasone (DEX) reduces virilization in girls with congenital adrenal hyperplasia (CAH). The treatment is effective but may result in long-lasting adverse effects. In this study we...
4.
Messina V, Hirvikoski T, Karlsson L, Vissani S, Wallensteen L, Ortolano R, et al.
Endocrine
. 2020 Mar;
68(2):427-437.
PMID: 32152914
Purpose: Patients with classic congenital adrenal hyperplasia (CAH) are treated postnatally with life-long glucocorticoid (GC) replacement therapy. Although prolonged exposure to GCs may have a negative impact on behaviour, few...
5.
Wallensteen L, Zimmermann M, Thomsen Sandberg M, Gezelius A, Nordenstrom A, Hirvikoski T, et al.
Horm Behav
. 2018 Aug;
103:140.
PMID: 30072011
No abstract available.
6.
Wallensteen L, Karlsson L, Messina V, Gezelius A, Thomsen Sandberg M, Nordenstrom A, et al.
Horm Behav
. 2018 Feb;
98:219-224.
PMID: 29410007
Prenatal dexamethasone (DEX) treatment in congenital adrenal hyperplasia (CAH) is effective in reducing virilization in affected girls, but potential long-term adverse effects are largely unknown. In this report we intended...
7.
Wallensteen L, Zimmermann M, Thomsen Sandberg M, Gezelius A, Nordenstrom A, Hirvikoski T, et al.
J Clin Endocrinol Metab
. 2016 Aug;
101(10):3838-3846.
PMID: 27482827
Context: Dexamethasone (DEX) is used to prevent virilization in female fetuses at risk of congenital adrenal hyperplasia (CAH). Given that treatment has to be started before the genotype is known,...
8.
Wallensteen L, Zimmermann M, Thomsen Sandberg M, Gezelius A, Nordenstrom A, Hirvikoski T, et al.
Horm Behav
. 2016 Jul;
85:5-11.
PMID: 27373757
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
This article has been retracted at the request of the authors due to technical errors that have...
9.
Flaring U, Lonnqvist P, Frenckner B, Svensson J, Ingolfsson I, Wallensteen L, et al.
BMC Pediatr
. 2011 Jul;
11:61.
PMID: 21729308
Background: Hyponatremia is the most frequent electrolyte abnormality observed in post-operative pediatric patients receiving intravenous maintenance fluid therapy. If plasma sodium concentration (p-Na+) declines to levels below 125 mmol/L in...